Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR CONTINUES COLLABORATION WITH LILLY
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).
Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.
November 2023
Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
Biocair, a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with Pharma.Aero, a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.
Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.
Source Genomics White Paper explores the transformative power of multi-omics in genomic research.
Multiomics combines the various ‘omics disciplines that make up the complex landscape of life science research. With the integration of genomic, transcriptomic, proteomic and epigenomic data, we obtain an advanced vision of the overarching framework behind all phenotypic outcomes.
AMSBIO has announced a new range of customizable ELISA assay kits designed to enable experienced researchers to achieve reliable and reproducible assay results.
With over 500 ELISA kits to choose from, the new range covers a wide variety of biological processes, targets, and sample types. Reagents such as matched antibody pairs and a micro-ELISA pre-plate have been carefully screened and validated to save you time and money.
Entire 11,000 sq ft next generation lab developed by Gen Two to become the British biotech company’s HQ
LONDON, 23 NOVEMBER 2023 – Constructive Bio
Innovate UK, a division of UK Research and Innovation, is offering an investment opportunity of up to £10 million for pioneering projects in advancing cancer immunotherapies and paediatric cancer treatments.
Projects may focus on: